I’m Not complaining and am holding my investment. However, my question is valid, legitimate and should be addressed.
I have run 4-5 small public companies in my career. I have been involved with losers and winners, the boring and the exciting. None of the companies I have run have disclosed as much in their quarterly reports as DECN does. It is not even close. So next week I expect much the same type of report that they have put out for years, a detailed description of their business, the good and the bad.
Will the report contain exactly what YOU are looking for, that I don't know. Will it contain everything Hurricane Willy is looking for, I doubt it because he is a trouble maker looking to force his way into a position of authority at the company so he can manipulate his own stock holdings. In his case, like the case of iHub posters, the most trouble they can cause the better.
DECN is an under resourced company that like many small companies makes decisions based on what they can afford to do. Willy has convinced many that the litmus for DECN should be a product that would require marketing budgets for 20 different International countries and reputable distributors to market the product. The two key words are budget and reputable.
Products take time to develop and bring to market. If you know a way to fund a development of another J&J product, test it in secrecy and bring it to market all before the J&J sale is complete, in what has been less than 120 days, then perhaps you should be the CEO. I read similar statements all the time on these message boards.
Forget all the trade names used, because any company can come up with a myriad of trade names. Even DECN owns its trade names. How many products does J&J have? They have 2. How many products does Roche have? They have 2. How many products does Abbott have? They have 2. How many products does Bayer have? They have 1 and 1/2. Except for Roche, and to an even lesser extent Bayer, all of the major products on the market were acquired from entrepreneurial companies over the years. All of these acquisitions were for single purpose, single technology products. The big pharmas might have been further developed the technologies over the years, but they did not develop the baseline technologies, they bought them. These four companies account for 78% of the overall testing market worldwide. How many products does DECN have? They have a multitude of technologies they are working on. Better questions are: How long does it take to bring a product to market? What does it cost them to do so? Do they have the resources of these other companies? Not even close, yet DECN is the subject of scorn and ridicule day in and day out. They can never do enough to satisfy basically anyone. Sad.
I, for one, will be disappointed if DECN spends any large chunk or time and explanation to talk about GenSure. GenSure can serve an interesting market, but it will be a company resource hog at a time when Mr. Berman is dealing with a declining stock price. Why should he use scarce resources or raise new money at these low stock prices to fund a resource hog? I guess only penny stock holders and traders have an answer to that question -- if they even understand the question.
I have run 4-5 small public companies in my career. I have been involved with losers and winners, the boring and the exciting. None of the companies I have run have disclosed as much in their quarterly reports as DECN does. It is not even close. So next week I expect much the same type of report that they have put out for years, a detailed description of their business, the good and the bad.
Will the report contain exactly what YOU are looking for, that I don't know. Will it contain everything Hurricane Willy is looking for, I doubt it because he is a trouble maker looking to force his way into a position of authority at the company so he can manipulate his own stock holdings. In his case, like the case of iHub posters, the most trouble they can cause the better.
DECN is an under resourced company that like many small companies makes decisions based on what they can afford to do. Willy has convinced many that the litmus for DECN should be a product that would require marketing budgets for 20 different International countries and reputable distributors to market the product. The two key words are budget and reputable.
Products take time to develop and bring to market. If you know a way to fund a development of another J&J product, test it in secrecy and bring it to market all before the J&J sale is complete, in what has been less than 120 days, then perhaps you should be the CEO. I read similar statements all the time on these message boards.
Forget all the trade names used, because any company can come up with a myriad of trade names. Even DECN owns its trade names. How many products does J&J have? They have 2. How many products does Roche have? They have 2. How many products does Abbott have? They have 2. How many products does Bayer have? They have 1 and 1/2. Except for Roche, and to an even lesser extent Bayer, all of the major products on the market were acquired from entrepreneurial companies over the years. All of these acquisitions were for single purpose, single technology products. The big pharmas might have been further developed the technologies over the years, but they did not develop the baseline technologies, they bought them. These four companies account for 78% of the overall testing market worldwide. How many products does DECN have? They have a multitude of technologies they are working on. Better questions are: How long does it take to bring a product to market? What does it cost them to do so? Do they have the resources of these other companies? Not even close, yet DECN is the subject of scorn and ridicule day in and day out. They can never do enough to satisfy basically anyone. Sad.
I, for one, will be disappointed if DECN spends any large chunk or time and explanation to talk about GenSure. GenSure can serve an interesting market, but it will be a company resource hog at a time when Mr. Berman is dealing with a declining stock price. Why should he use scarce resources or raise new money at these low stock prices to fund a resource hog? I guess only penny stock holders and traders have an answer to that question -- if they even understand the question.
7
